Terms: = Skin cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2
540 results:
1. Cross-Species Comparison of the Pan-RAF Inhibitor LY3009120's Anti-Tumor Effects in Equine, Canine, and Human Malignant Melanoma Cell Lines.
Gao Y; Packeiser EM; Wendt S; Sekora A; Cavalleri JV; Pratscher B; Alammar M; Hühns M; Brenig B; Junghanss C; Nolte I; Murua Escobar H
Genes (Basel); 2024 Feb; 15(2):. PubMed ID: 38397192
[TBL] [Abstract] [Full Text] [Related]
2. FOXM1 promote the growth and metastasis of uveal melanoma cells by regulating CDK2 expression.
Bai X; Li S; Luo Y
Int Ophthalmol; 2024 Feb; 44(1):55. PubMed ID: 38342795
[TBL] [Abstract] [Full Text] [Related]
3. ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes.
Akinjiyan FA; Nassief G; Phillipps J; Adeyelu T; Elliott A; Abdulla F; Zhou AY; Souroullas G; Kim KB; Vanderwalde A; Park SJ; Ansstas G
Sci Rep; 2024 Feb; 14(1):3444. PubMed ID: 38341515
[TBL] [Abstract] [Full Text] [Related]
4. NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth.
Cai C; Tu J; Najarro J; Zhang R; Fan H; Zhang FQ; Li J; Xie Z; Su R; Dong L; Arellano N; Ciboddo M; Elf SE; Gao X; Chen J; Wu R
Mol Cancer Res; 2024 Apr; 22(4):386-401. PubMed ID: 38294692
[TBL] [Abstract] [Full Text] [Related]
5. Mosaic RASopathies concept: different skin lesions, same systemic manifestations?
Morren MA; Fodstad H; Brems H; Bedoni N; Guenova E; Jacot-Guillarmod M; Busiah K; Giuliano F; Gilliet M; Atallah I
J Med Genet; 2024 Apr; 61(5):411-419. PubMed ID: 38290824
[TBL] [Abstract] [Full Text] [Related]
6. Liprin-α1 contributes to oncogenic MAPK signaling by counteracting ERK activity.
Pehkonen H; Filippou A; Väänänen J; Lindfors I; Vänttinen M; Ianevski P; Mäkelä A; Munne P; Klefström J; Toppila-Salmi S; Grénman R; Hagström J; Mäkitie AA; Karhemo PR; Monni O
Mol Oncol; 2024 Mar; 18(3):662-676. PubMed ID: 38264964
[TBL] [Abstract] [Full Text] [Related]
7. Multiomics characterization of pyroptosis in the tumor microenvironment and therapeutic relevance in metastatic melanoma.
Chen W; He Y; Zhou G; Chen X; Ye Y; Zhang G; Liu H
BMC Med; 2024 Jan; 22(1):24. PubMed ID: 38229080
[TBL] [Abstract] [Full Text] [Related]
8. Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma.
Neville G; Marzario B; Shilling D; Hand CK; Heffron C
Virchows Arch; 2024 Mar; 484(3):475-479. PubMed ID: 38183457
[TBL] [Abstract] [Full Text] [Related]
9. Metastatic Undifferentiated Melanoma Mimicking a Primary Bone Tumor: A Potential Diagnostic Pitfall.
Wills A; Dibbern M; Frierson HF; Raghavan SS
Am J Dermatopathol; 2024 Mar; 46(3):170-172. PubMed ID: 38170737
[TBL] [Abstract] [Full Text] [Related]
10. A Phase 1b/2a Study of GC1118 with 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in Patients with Recurrent or Metastatic Colorectal cancer.
Lee KW; Han SW; Kim TW; Ahn JB; Baek JY; Cho SH; Lee H; Kim JW; Kim JW; Kim TY; Hong YS; Beom SH; Cha Y; Choi Y; Kim S; Bang YJ
Cancer Res Treat; 2024 Apr; 56(2):590-601. PubMed ID: 38062706
[TBL] [Abstract] [Full Text] [Related]
11. Immunohistochemical and Molecular Characteristics of Anogenital Papillary Hidradenomas.
Karpathiou G; Sim A; Picot T; Mekhzoumi K; Chauleur C; Péoc'h M
Am J Dermatopathol; 2024 Feb; 46(2):79-82. PubMed ID: 38055985
[TBL] [Abstract] [Full Text] [Related]
12. First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.
Janku F; Kim TM; Iyer G; Spreafico A; Elez E; de Jonge M; Yamamoto N; van der Wekken AJ; Ascierto PA; Maur M; Marmé F; Kiladjian JJ; Basu S; Baffert F; Buigues A; Chen C; Cooke V; Giorgetti E; Kim J; McCarthy F; Moschetta M; Dummer R
Eur J Cancer; 2024 Jan; 196():113458. PubMed ID: 38039779
[TBL] [Abstract] [Full Text] [Related]
13. Sotorasib plus Panitumumab in Refractory Colorectal cancer with Mutated
Fakih MG; Salvatore L; Esaki T; Modest DP; Lopez-Bravo DP; Taieb J; Karamouzis MV; Ruiz-Garcia E; Kim TW; Kuboki Y; Meriggi F; Cunningham D; Yeh KH; Chan E; Chao J; Saportas Y; Tran Q; Cremolini C; Pietrantonio F
N Engl J Med; 2023 Dec; 389(23):2125-2139. PubMed ID: 37870968
[TBL] [Abstract] [Full Text] [Related]
14. Pathway-driven analysis of synthetic lethal interactions in cancer using perturbation screens.
Karimpour M; Totonchi M; Behmanesh M; Montazeri H
Life Sci Alliance; 2024 Jan; 7(1):. PubMed ID: 37863651
[TBL] [Abstract] [Full Text] [Related]
15. Advancements and perspectives of RBX2 as a molecular hallmark in cancer.
Tao Y; Dai L; Liang W; Li X; Lyu Y; Li J; Li Z; Shi Z; Liang X; Zhou S; Fu X; Hu W; Wang X
Gene; 2024 Jan; 892():147864. PubMed ID: 37820940
[TBL] [Abstract] [Full Text] [Related]
16. Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced kras Wild Type Colorectal cancer.
Jiang DM; Parshad S; Zhan L; Sim HW; Siu LL; Liu G; Shapiro JD; Price TJ; Jonker DJ; Karapetis CS; Strickland AH; Zhang W; Jeffery M; Tu D; Ng S; Sabesan S; Shannon J; Townsend A; O'Callaghan CJ; Chen EX
Clin Colorectal Cancer; 2023 Dec; 22(4):457-463. PubMed ID: 37704538
[TBL] [Abstract] [Full Text] [Related]
17. Primary mucosal melanomas of the urogenital tract: a clinical, pathological, and genetic nationwide survey of Danish patients 1990-2019.
Znaider VK; Mikkelsen LH; Jensen CFS; Sønksen J; Heegaard S
Scand J Urol; 2023 Aug; 58():52-59. PubMed ID: 37635444
[TBL] [Abstract] [Full Text] [Related]
18. NTRK expression is common in xanthogranuloma and is associated with the solitary variant.
Umphress B; Kuhar M; Kowal R; Alomari AK; Baldridge LA; Ross AJ; Warren SJ
J Cutan Pathol; 2023 Nov; 50(11):991-1000. PubMed ID: 37580954
[TBL] [Abstract] [Full Text] [Related]
19. Non-SMC condensin I complex subunit D2 (NCAPD2) reveals its prognostic and immunologic features in human cancers.
Dong X; Liu T; Li Z; Zhai Y
Aging (Albany NY); 2023 Jul; 15(14):7237-7257. PubMed ID: 37498296
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic biomarkers for survival in mucosal melanoma.
Thierauf JC; Kaluziak ST; Codd E; Dybel SN; Jobbagy S; Purohit R; Farahani AA; Dedeilia A; Naranbhai V; Hoang MP; Fisch AS; Ritterhouse L; Boland GM; Lennerz JK; Iafrate AJ
Pigment Cell Melanoma Res; 2023 Sep; 36(5):378-387. PubMed ID: 37390098
[TBL] [Abstract] [Full Text] [Related]
[Next]
